VIPROSTOL

Details

Stereochemistry	MIXED
Molecular Formula	C23H36O5
Molecular Weight	392.5289
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 4
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCC(O)(C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(=O)OC)C=C

InChI

InChIKey=TWCQWABAGCMHLL-ROVQGQOSSA-N

InChI=1S/C23H36O5/c1-4-6-15-23(27,5-2)16-11-13-19-18(20(24)17-21(19)25)12-9-7-8-10-14-22(26)28-3/h5,7,9,11,13,18-19,21,25,27H,2,4,6,8,10,12,14-17H2,1,3H3/b9-7-,13-11+/t18-,19-,21-,23?/m1/s1

HIDE SMILES / InChI

Molecular Formula	C23H36O5
Molecular Weight	392.5289
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	3 / 4
E/Z Centers	2
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2212146 | https://www.ncbi.nlm.nih.gov/pubmed/4083568

Viprostol (also known as CL115,347), a prostaglandin E2 congener that was studied as an antihypertensive agent. Viprostol has a potent and prolonged blood pressure lowering effect in many models of hypertension. In clinical studies, viprostol has been demonstrated to lower arterial blood pressure significantly in man following transdermal and/or intravenous administration. The antihypertensive action of viprostol has been suggested to be the result of peripheral vasodilatation. In addition, the drug participated in a clinical trial in normal subjects and in patients with Raynaud's phenomenon. It was found the optimal dosage was 1000 ug; the effect could last for 84 hours; higher dosage may be associated with a "steal" phenomenon.

Approval Year

PubMed

Title	Date	PubMed
CL 115,347 (DHV-PGE2 ME): a new orally and topically active prostaglandin antihypertensive agent.	1983 Feb	6571821
Antilipolytic activity of viprostol, a transdermally active antihypertensive PGE2 analog.	1987 May	2438724
Deposition of viprostol (a synthetic PGE2 vasodilator) in the skin following topical administration to laboratory animals.	1987 Sep	3120427
Pre-systemic metabolism of viprostol in the monkey following oral and topical administration.	1988 Jul	3176518
Transdermal viprostol in the treatment of male pattern baldness.	1990 Sep	2212146

Sample Use Guides

In Vivo Use Guide

substance is absorbed transdermally from a patch placed on the skin. In a placebo-controlled trial the vasodilatory effect of single incremental dosage, 500 mcg, 1000 mcg and 1500 mcg

Route of Administration: Transdermal

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:16:20 GMT 2023` Edited by `admin` on `Fri Dec 15 16:16:20 GMT 2023`
Record UNII	O2Y6I4Y8TF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VIPROSTOL

Official Name

English

VIPROSTOL [MART.]

Common Name

English

VIPROSTOL [USAN]

Common Name

English

PROSTA-5,13-DIEN-1-OIC ACID, 16-ETHENYL-11,16-DIHYDROXY-9-OXO-, METHYL ESTER, (5Z,11A,13E)-(±)-

Common Name

English

viprostol [INN]

Common Name

English

CL 115,347

Code

English

CL-115347

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C78568